Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Blood (2024) 144 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2024-208083

Published: 2024

Journal Articles

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Blood (2024) 144 (Supplement 1): 3510.

https://doi.org/10.1182/blood-2024-207118

Published: 2024

Journal Articles

Outcomes of 9/10 Mmud Allo-HCT Using Ptcy-TK Prophylaxis. Results from a Single Institution

Filipe Pinto, Alexandra Pedraza, Maria Suarez-Lledo, Laia Guardia, Paola Charry, Joan Cid, Miquel Lozano, Gerard Corrius, Noemí De Llobet, Enric Carreras, Laura Rosiñol Dachs, Francesc Fernández-Avilés, Montserrat Rovira, Carmen Martinez, Maria Queralt Salas, Jordi Esteve Reyner

Blood (2024) 144 (Supplement 1): 7342.

https://doi.org/10.1182/blood-2024-207563

Published: 2024

Journal Articles

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

Blood (2024) 144 (Supplement 1): 787.

https://doi.org/10.1182/blood-2024-204867

Published: 2024

Journal Articles

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Beatriz Merchán Muñoz, Alexandra Martínez-Roca, Nuria Ballestar, Cristina Gallego, Nuria Martínez-Cibrián, Valentin Ortiz-Maldonado, Luis Gerardo Rodriguez-Lobato, Nil Albiol, Pilar Ayora, Carla Ramos, Maria Sanchez-Castañon, Manel Juan, Julio Delgado, Jordi Esteve Reyner, Alvaro Urbano-Ispizua, Carlos Fernández de Larrea, Francesc Fernández-Avilés

Blood (2024) 144 (Supplement 1): 7619.

https://doi.org/10.1182/blood-2024-211330

Published: 2024

Journal Articles

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Blood (2023) 142 (Supplement 1): 2200.

https://doi.org/10.1182/blood-2023-186687

Published: 2023

Journal Articles

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2023-185484

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2023-181076

Published: 2023

Journal Articles

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Blood (2022) 140 (Supplement 1): 4730–4732.

https://doi.org/10.1182/blood-2022-170498

Published: 2022

Journal Articles

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

María Queralt Salas, Paola Charry, Nuria Martínez-Cibrian, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Marc Brusosa, María Teresa Solano, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Jordi Arcarons, Noemí Llobet, Laura Rosinol Dachs, Jordi Esteve, Álvaro Urbano-Ispizua, Enric Carreras, Francesc Fernández-Avilés, Maria Carmen Martinez Munoz, Montserrat Rovira

Blood (2022) 140 (Supplement 1): 4772–4773.

https://doi.org/10.1182/blood-2022-170407

Published: 2022

Journal Articles

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Blood (2022) 140 (Supplement 1): 7616–7618.

https://doi.org/10.1182/blood-2022-167051

Published: 2022

Journal Articles

Endotheliopathy, Innate-Immune Activation and Hemostatic Misbalance Underlying CAR-T Cell Toxicities: Tools for Early and Differential Diagnosis

Ana Belén Moreno-Castaño, Sara Fernandez, Marta Palomo, Julia Martinez-Sanchez, Alex Ramos, Patricia Molina, Marc Pino, Valentín Ortiz-Maldonado, Julio Delgado, Carlos Fernández De Larrea, Álvaro Urbano-Ispizua, Gines Escolar, Enric Carreras, Francesc Fernández-Avilés, Pedro Castro, Maribel Diaz-Ricart

Blood (2022) 140 (Supplement 1): 7427–7428.

https://doi.org/10.1182/blood-2022-169293

Published: 2022

Journal Articles

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Blood (2021) 138 (Supplement 1): 3925.

https://doi.org/10.1182/blood-2021-153069

Published: 2021

Journal Articles

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Paola Andrea Charry, Maria Queralt Salas, Alexandra Pedraza, María Suárez-Lledó, Nuria Martínez-Cibrian, Teresa Solano, Ariadna Domenech, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, Laura Rosinol, Francesc Fernández-Avilés, Gonzalo Gutiérrez-García, Enric Carreras, Jordi Esteve, Álvaro Urbano-Ispizua, Montserrat Rovira, Carmen Martínez

Blood (2021) 138 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2021-153366

Published: 2021

Journal Articles

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Patricia Ferraz, MD, Arturo Pereira, MD PhD, María Suárez-Lledó, MD, Gonzalo Gutiérrez-García, MD, Francesc Fernández-Avilés, MD, Laura Rosinol, MD PhD, Teresa Solano, Noemí Llobet, Carla Ramos, Pedro Marín, MD, Alvaro Urbano-Ispizua, MD, Montserrat Rovira, MD, Carmen Martinez, MD PhD

Blood (2018) 132 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2018-99-112985

Published: 2018

Journal Articles

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH)

Blood (2018) 132 (Supplement 1): 200.

https://doi.org/10.1182/blood-2018-200

Published: 2018

Journal Articles

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Blood (2016) 128 (22): 3436.

https://doi.org/10.1182/blood.V128.22.3436.3436

Published: 2016

Journal Articles

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Nuria Martinez-Cibrian, Teresa Garrido, Arturo Pereira, Mauricio Sarmiento, Jose Antonio Pérez-Simón, Rocio Parody, MD, Estefania Perez, Oriana Lopez, Carlos Solano, Jose Luis Piñana, Montserrat Rovira, Francesc Fernandez-Avilés, Maria Suarez-Lledo, Alvaro Urbano-Ispizua, Carmen Martinez, MD PhD

Blood (2015) 126 (23): 5464.

https://doi.org/10.1182/blood.V126.23.5464.5464

Published: 2015

NARROW

M-Easix (Better Than EASIX) Correlates with Specific Endotheliopathy Biomarkers, Predicts Severe CAR-T Cell Toxicities and Discriminates from Sepsis

Frailty Syndrome Is Associated with Increased Endothelial Activation and Post-Transplant Complications in Allo-HCT Patients

Outcomes of 9/10 Mmud Allo-HCT Using Ptcy-TK Prophylaxis. Results from a Single Institution

Transforming Frailty Care in Allo-HCT Candidates: A Prospective Assessment of a Tele-Prehabilitation Project

Outpatient Reinfusion of CAR-T Cesnicabtagene Autoleucel (ARI0002h) in Multiple Myeloma Is Feasible and Safe

Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on the Immune Reconstitution and the Incidence of Infectious Complications

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Impact of Ptcy-Based Prophylaxis on Early Infectious Complications in Adults Undergoing Peripheral Blood Allo-HCT

Impressive Reduction of Gvhd Incidence Using Ptcy-TK for Gvhd Prevention in Adults Undergoing 10/10 HLA-Matched Peripheral Blood Allo-HCT

Easix Application in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Prophylaxis

Endotheliopathy, Innate-Immune Activation and Hemostatic Misbalance Underlying CAR-T Cell Toxicities: Tools for Early and Differential Diagnosis

Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era

Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Post-Transplant High-Dose Cyclophosphamide Overcomes the Detrimental Effect of a Single-Locus HLA Mismatched in Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplantation

Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH)

Response to Proteosome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study

Association Between Uric Acid Levels and Severe Acute Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only